Teva Pharmaceutical Industries Ltd.
|Applicable indicator||Not applicable|
Teva is a prominent producer of antibiotics globally by sales volume. As a generic medicine manufacturer, Teva was evaluated in Manufacturing & Production and Appropriate Access & Stewardship only. The company performs well when compared with the other generic medicine manufacturers in scope. It discloses a comprehensive environmental risk-management strategy, which it does not apply to third-party manufacturers of antibiotic APIs and drug products or to external waste-treatment plants. The company reports that it has mechanisms for maintaining a high quality of antibiotic production, and requires its third-party suppliers to apply the same quality standards to their production facilities. Teva reported no information on its access strategies regarding antimicrobial medicines in countries in scope* or its involvement in stewardship activities that promote appropriate antibiotic use.
Sales & operations
Teva is an Israeli-based generic medicine manufacturer founded in 1901. The company operates in two business segments: generic and specialty medicines. Its specialty medicines segment focuses on delivering medicines, devices and services in the core therapeutic areas of respiratory illness, central nervous system (including pain, migraine, movement and neurodegenerative disorders), oncology and women’s health. It engages in R&D activities within both its business segments, focusing on the development of complex technologies and formulations. Teva is active in 80 countries and has 87 manufacturing facilities, manufacturing and supplying active pharmaceutical ingredients on a global scale. It also has a global over-the-counter (OTC) business, including a collaboration with Procter & Gamble called PGT Healthcare. Teva has the highest revenue among the generic medicine manufacturers included in the Benchmark. The company markets its antimicrobial medicines in 54 countries globally, seven of which are low- or middle-income countries.* In 2016, Teva acquired Actavis Generics, the global generic pharmaceuticals business from Allergan plc, for approximately USD 33.4 billion cash and 100 million Teva shares. The acquisition required the divestment of certain assets and operations in the USA and Europe to meet antitrust regulatory requirements. Later in 2016, the company completed the acquisition of Anda Inc., a US-based distributor of generic pharmaceuticals from Allergan for USD 500 million.
Teva markets at least 44 antimicrobial medicines, 30 of which are listed on the WHO EML (Section 6). Twenty-eight of the company’s antimicrobial medicines are antibiotics, with 17 listed on the WHO EML (Section 6), including one on the EML’s Reserve group (linezolid). The remaining 16 medicines consist of nine antivirals, four antifungals and three antiprotozoals indicated for treatment of malaria.
Engage in antimicrobial stewardship. Teva can engage in stewardship activities, e.g., through surveillance activities, educational activities for healthcare professionals on AMR (while mitigating conflicts of interest), and engage in appropriate promotion practices.
Ensure affordability and registration plans for new and existing antimicrobials. Teva can seek to improve access in low- and middle-income countries through the registration of new and existing antimicrobials, and ensure that they are priced affordably. Currently, the company does not disclose such information.
Improve transparency regarding environmental risk management. Teva can share more information on how it manages environmental risk, e.g., disclose the levels of antibiotic discharge and publish the identities of third parties who manufacture antibiotic APIs and drug products on its behalf. Teva currently discloses its environmental risk-management principles.
Expand environmental risk-management strategy. Teva has an environmental risk-management strategy that includes discharge limits, which are applied to its own manufacturing sites. It can ensure its environmental risk-management strategy is applied to external waste treatment plants and can apply its discharge limits and auditing processes to third-party suppliers of antibiotic APIs and drug products.
Engage in R&D innovation. Teva can engage in incremental R&D innovation to address resistance, improve adherence and the appropriate use of antimicrobial medicines.
A. Research & Development
As a generic medicine manufacturer, Teva’s main focus is the manufacturing of generic products and as such was not in scope for this Research Area.
B. Manufacturing & Production
B.1 Environmental risk-management strategy for own sites.
Teva applies an environmental risk-management strategy to minimise the impact of antibiotic manufacturing discharge that includes auditing and discharge limits. The strategy applies to Teva’s own sites and to its third-party manufacturers of antibiotic APIs and drug products, however the discharge limits and auditing processes are applicable to its own manufacturing sites only. The strategy does not apply to external waste-treatment plants.
B.2 Limited transparency regarding environmental risk management.
Teva publishes its environmental risk-management strategy in its CSR report. It does not disclose audit results, or the discharge levels of antibiotics. The company also does not share the identities of its third-party suppliers of antibiotic APIs and drug products or external waste-treatment plants.
B.3 Commits to following GMP, including at 3rd-party sites.
Teva reports that it has mechanisms for maintaining a high quality of antibiotic production — namely following GMP standards. This commitment applies to its own manufacturing sites. Teva requires its third-party suppliers to apply the same quality standards to their production facilities.
C. Appropriate Access & Stewardship
C.1 No information on filing for registration.
Teva reports no information on where it has filed its newest antibiotics for registration in countries in scope*. This information is not otherwise publicly available.
C.2 No disclosure on equitable pricing approach.
Teva does not disclose an equitable pricing approach for its highest-volume antibiotics and/or antimicrobial medicines.
C.3 No insight into steps addressing supply chain efficiency.
Teva does not disclose how it works with stakeholders (e.g., governments, procurers) to align supply and demand for antimicrobial medicines, specifically to prevent or minimise stock-outs in countries in scope*. The company also does not report on whether it has processes in place to respond to stock-outs in countries in scope*.
C.4-C.7 No apparent involvement in stewardship activities.
Teva does not report any involvement in stewardship activities (from education to surveillance to appropriate promotion practices) that promote appropriate antibiotic use.
* Countries in scope are 106 low- and middle-income countries where access to medicine is likely limited
† EML Section 6: Anti-Infective Medicines
§ Net revenues; FYE 31 December 2016